[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fq0GATHf16A0c5wMYFN9VnUbkOYr8uLeyMirjt08vvHo":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":44,"rows":51},"Azienda Ospedaliera Universitaria Integrata Verona",[4],94,false,18,9,42105,2,79,[14,17,20,22,25,27,29,31],{"name":15,"count":16},"Postoperative Complications",5,{"name":18,"count":19},"Pancreatic Cancer",4,{"name":21,"count":19},"Pancreatic Fistula",{"name":23,"count":24},"Obesity",3,{"name":26,"count":24},"Surgical Site Infection",{"name":28,"count":24},"COVID-19",{"name":30,"count":11},"Fibromyalgia",{"name":32,"count":11},"Endoscopic Ultrasound",[34,39],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT05303714","PIPAC in Multimodal Therapy for Patients with Oligometastatic Peritoneal Gastric Cancer","2025-09-30","FOLFOX and PIPAC",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT07289035","Early Study on Tamoxifen Safety\u002FTolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators.","2026-04-01","Tamoxifen Citrate 20Mg Tab",[45,46,47,48,49,50],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[52,77,100,141,173,191,209,227,245,263,281,299,317,356,383,409,427,445,463,481,499,523,549,575,600,625],{"intervention":38,"totalTrials":53,"cells":54},1,{"EARLY_PHASE1":55,"PHASE1":58,"PHASE2":60,"PHASE3":62,"PHASE4":73,"NA":75},{"trials":56,"activeCount":57},[],0,{"trials":59,"activeCount":57},[],{"trials":61,"activeCount":57},[],{"trials":63,"activeCount":53,"soonestReadout":37},[64],{"nctId":35,"briefTitle":36,"status":65,"phases":66,"primaryCompletion":37,"completion":67,"start":68,"enrollment":69,"conditions":70,"interventions":72},"RECRUITING",[48],"2028-09-30","2022-03-31",98,[71],"Oligometastatic Gastric Adenocarcinoma",[38],{"trials":74,"activeCount":57},[],{"trials":76,"activeCount":57},[],{"intervention":43,"totalTrials":53,"cells":78},{"EARLY_PHASE1":79,"PHASE1":81,"PHASE2":83,"PHASE3":94,"PHASE4":96,"NA":98},{"trials":80,"activeCount":57},[],{"trials":82,"activeCount":57},[],{"trials":84,"activeCount":53,"soonestReadout":42},[85],{"nctId":40,"briefTitle":41,"status":86,"phases":87,"primaryCompletion":42,"completion":88,"start":89,"enrollment":90,"conditions":91,"interventions":93},"NOT_YET_RECRUITING",[47],"2027-02-01","2026-01-15",35,[92],"Cystic Fibrosis - Complete",[43],{"trials":95,"activeCount":57},[],{"trials":97,"activeCount":57},[],{"trials":99,"activeCount":57},[],{"intervention":101,"totalTrials":11,"cells":102},"Folic acid",{"EARLY_PHASE1":103,"PHASE1":105,"PHASE2":107,"PHASE3":109,"PHASE4":124,"NA":139},{"trials":104,"activeCount":57},[],{"trials":106,"activeCount":57},[],{"trials":108,"activeCount":57},[],{"trials":110,"activeCount":57},[111],{"nctId":112,"briefTitle":113,"status":114,"phases":115,"primaryCompletion":116,"completion":117,"start":118,"enrollment":119,"conditions":120,"interventions":122},"NCT01244347","Folic Acid Dosage and Malformations Reduction","UNKNOWN",[48],"2015-09","2016-09","2009-07",5000,[121],"Congenital Malformations",[123,123],"folic acid",{"trials":125,"activeCount":57},[126],{"nctId":127,"briefTitle":128,"status":114,"phases":129,"primaryCompletion":130,"completion":130,"start":131,"enrollment":132,"conditions":133,"interventions":136},"NCT05505006","Management of Preoperative Anaemia in Surgical Oncology",[49],"2024-08-13","2021-03-02",500,[134,135],"Anemia","Tumor",[137,101,138],"Ferric Carboxymaltose","B12",{"trials":140,"activeCount":57},[],{"intervention":142,"totalTrials":53,"cells":143},"Vortioxetine",{"EARLY_PHASE1":144,"PHASE1":146,"PHASE2":148,"PHASE3":150,"PHASE4":152,"NA":171},{"trials":145,"activeCount":57},[],{"trials":147,"activeCount":57},[],{"trials":149,"activeCount":57},[],{"trials":151,"activeCount":57},[],{"trials":153,"activeCount":57},[154],{"nctId":155,"briefTitle":156,"status":157,"phases":158,"primaryCompletion":159,"completion":159,"start":160,"enrollment":161,"conditions":162,"interventions":164},"NCT03779789","Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment","COMPLETED",[49],"2023-02-28","2019-02-01",362,[163],"Major Depressive Disorder",[142,165,166,167,168,169,170],"Sertraline","citalopram","Escitalopram","Paroxetine","Fluoxetine","Fluvoxamine",{"trials":172,"activeCount":57},[],{"intervention":165,"totalTrials":53,"cells":174},{"EARLY_PHASE1":175,"PHASE1":177,"PHASE2":179,"PHASE3":181,"PHASE4":183,"NA":189},{"trials":176,"activeCount":57},[],{"trials":178,"activeCount":57},[],{"trials":180,"activeCount":57},[],{"trials":182,"activeCount":57},[],{"trials":184,"activeCount":57},[185],{"nctId":155,"briefTitle":156,"status":157,"phases":186,"primaryCompletion":159,"completion":159,"start":160,"enrollment":161,"conditions":187,"interventions":188},[49],[163],[142,165,166,167,168,169,170],{"trials":190,"activeCount":57},[],{"intervention":166,"totalTrials":53,"cells":192},{"EARLY_PHASE1":193,"PHASE1":195,"PHASE2":197,"PHASE3":199,"PHASE4":201,"NA":207},{"trials":194,"activeCount":57},[],{"trials":196,"activeCount":57},[],{"trials":198,"activeCount":57},[],{"trials":200,"activeCount":57},[],{"trials":202,"activeCount":57},[203],{"nctId":155,"briefTitle":156,"status":157,"phases":204,"primaryCompletion":159,"completion":159,"start":160,"enrollment":161,"conditions":205,"interventions":206},[49],[163],[142,165,166,167,168,169,170],{"trials":208,"activeCount":57},[],{"intervention":167,"totalTrials":53,"cells":210},{"EARLY_PHASE1":211,"PHASE1":213,"PHASE2":215,"PHASE3":217,"PHASE4":219,"NA":225},{"trials":212,"activeCount":57},[],{"trials":214,"activeCount":57},[],{"trials":216,"activeCount":57},[],{"trials":218,"activeCount":57},[],{"trials":220,"activeCount":57},[221],{"nctId":155,"briefTitle":156,"status":157,"phases":222,"primaryCompletion":159,"completion":159,"start":160,"enrollment":161,"conditions":223,"interventions":224},[49],[163],[142,165,166,167,168,169,170],{"trials":226,"activeCount":57},[],{"intervention":168,"totalTrials":53,"cells":228},{"EARLY_PHASE1":229,"PHASE1":231,"PHASE2":233,"PHASE3":235,"PHASE4":237,"NA":243},{"trials":230,"activeCount":57},[],{"trials":232,"activeCount":57},[],{"trials":234,"activeCount":57},[],{"trials":236,"activeCount":57},[],{"trials":238,"activeCount":57},[239],{"nctId":155,"briefTitle":156,"status":157,"phases":240,"primaryCompletion":159,"completion":159,"start":160,"enrollment":161,"conditions":241,"interventions":242},[49],[163],[142,165,166,167,168,169,170],{"trials":244,"activeCount":57},[],{"intervention":169,"totalTrials":53,"cells":246},{"EARLY_PHASE1":247,"PHASE1":249,"PHASE2":251,"PHASE3":253,"PHASE4":255,"NA":261},{"trials":248,"activeCount":57},[],{"trials":250,"activeCount":57},[],{"trials":252,"activeCount":57},[],{"trials":254,"activeCount":57},[],{"trials":256,"activeCount":57},[257],{"nctId":155,"briefTitle":156,"status":157,"phases":258,"primaryCompletion":159,"completion":159,"start":160,"enrollment":161,"conditions":259,"interventions":260},[49],[163],[142,165,166,167,168,169,170],{"trials":262,"activeCount":57},[],{"intervention":170,"totalTrials":53,"cells":264},{"EARLY_PHASE1":265,"PHASE1":267,"PHASE2":269,"PHASE3":271,"PHASE4":273,"NA":279},{"trials":266,"activeCount":57},[],{"trials":268,"activeCount":57},[],{"trials":270,"activeCount":57},[],{"trials":272,"activeCount":57},[],{"trials":274,"activeCount":57},[275],{"nctId":155,"briefTitle":156,"status":157,"phases":276,"primaryCompletion":159,"completion":159,"start":160,"enrollment":161,"conditions":277,"interventions":278},[49],[163],[142,165,166,167,168,169,170],{"trials":280,"activeCount":57},[],{"intervention":137,"totalTrials":53,"cells":282},{"EARLY_PHASE1":283,"PHASE1":285,"PHASE2":287,"PHASE3":289,"PHASE4":291,"NA":297},{"trials":284,"activeCount":57},[],{"trials":286,"activeCount":57},[],{"trials":288,"activeCount":57},[],{"trials":290,"activeCount":57},[],{"trials":292,"activeCount":57},[293],{"nctId":127,"briefTitle":128,"status":114,"phases":294,"primaryCompletion":130,"completion":130,"start":131,"enrollment":132,"conditions":295,"interventions":296},[49],[134,135],[137,101,138],{"trials":298,"activeCount":57},[],{"intervention":138,"totalTrials":53,"cells":300},{"EARLY_PHASE1":301,"PHASE1":303,"PHASE2":305,"PHASE3":307,"PHASE4":309,"NA":315},{"trials":302,"activeCount":57},[],{"trials":304,"activeCount":57},[],{"trials":306,"activeCount":57},[],{"trials":308,"activeCount":57},[],{"trials":310,"activeCount":57},[311],{"nctId":127,"briefTitle":128,"status":114,"phases":312,"primaryCompletion":130,"completion":130,"start":131,"enrollment":132,"conditions":313,"interventions":314},[49],[134,135],[137,101,138],{"trials":316,"activeCount":57},[],{"intervention":318,"totalTrials":11,"cells":319},"Sotrovimab",{"EARLY_PHASE1":320,"PHASE1":322,"PHASE2":324,"PHASE3":326,"PHASE4":352,"NA":354},{"trials":321,"activeCount":57},[],{"trials":323,"activeCount":57},[],{"trials":325,"activeCount":57},[],{"trials":327,"activeCount":57},[328,339],{"nctId":329,"briefTitle":330,"status":157,"phases":331,"primaryCompletion":332,"completion":332,"start":333,"enrollment":334,"conditions":335,"interventions":336},"NCT05321394","Non-inferiority Trial on Treatments in Early COVID-19",[48],"2023-10-29","2022-03-07",536,[28],[318,337,338],"Tixagevimab Cilgavimab","Nirmatrelvir Ritonavir",{"nctId":340,"briefTitle":341,"status":342,"phases":343,"primaryCompletion":344,"completion":345,"start":346,"enrollment":347,"conditions":348,"interventions":349},"NCT05205759","Non-inferiority Trial on Monoclonal Antibodies in COVID-19","TERMINATED",[48],"2022-02-05","2022-04-05","2021-12-09",319,[28],[350,318,351],"Bamlanivimab Etesevimab","Casirivimab-Imdevimab",{"trials":353,"activeCount":57},[],{"trials":355,"activeCount":57},[],{"intervention":357,"totalTrials":53,"cells":358},"Prasugrel Hydrochloride 10 MG Oral",{"EARLY_PHASE1":359,"PHASE1":361,"PHASE2":363,"PHASE3":365,"PHASE4":379,"NA":381},{"trials":360,"activeCount":57},[],{"trials":362,"activeCount":57},[],{"trials":364,"activeCount":57},[],{"trials":366,"activeCount":57},[367],{"nctId":368,"briefTitle":369,"status":114,"phases":370,"primaryCompletion":371,"completion":372,"start":373,"enrollment":374,"conditions":375,"interventions":378},"NCT04445623","Prasugrel in Severe COVID-19 Pneumonia",[48],"2020-10","2021-01","2020-07",128,[376,377],"COVID19","Thrombosis",[357],{"trials":380,"activeCount":57},[],{"trials":382,"activeCount":57},[],{"intervention":384,"totalTrials":53,"cells":385},"intravenous immunoglobulins",{"EARLY_PHASE1":386,"PHASE1":388,"PHASE2":390,"PHASE3":392,"PHASE4":405,"NA":407},{"trials":387,"activeCount":57},[],{"trials":389,"activeCount":57},[],{"trials":391,"activeCount":57},[],{"trials":393,"activeCount":57},[394],{"nctId":395,"briefTitle":396,"status":157,"phases":397,"primaryCompletion":398,"start":399,"enrollment":400,"conditions":401,"interventions":403},"NCT01537575","Intravenous Immunoglobulins for Post-Polio Syndrome",[48],"2009-12","2008-01",50,[402],"Post-polio Syndrome",[384,404],"Saline solution",{"trials":406,"activeCount":57},[],{"trials":408,"activeCount":57},[],{"intervention":404,"totalTrials":53,"cells":410},{"EARLY_PHASE1":411,"PHASE1":413,"PHASE2":415,"PHASE3":417,"PHASE4":423,"NA":425},{"trials":412,"activeCount":57},[],{"trials":414,"activeCount":57},[],{"trials":416,"activeCount":57},[],{"trials":418,"activeCount":57},[419],{"nctId":395,"briefTitle":396,"status":157,"phases":420,"primaryCompletion":398,"start":399,"enrollment":400,"conditions":421,"interventions":422},[48],[402],[384,404],{"trials":424,"activeCount":57},[],{"trials":426,"activeCount":57},[],{"intervention":337,"totalTrials":53,"cells":428},{"EARLY_PHASE1":429,"PHASE1":431,"PHASE2":433,"PHASE3":435,"PHASE4":441,"NA":443},{"trials":430,"activeCount":57},[],{"trials":432,"activeCount":57},[],{"trials":434,"activeCount":57},[],{"trials":436,"activeCount":57},[437],{"nctId":329,"briefTitle":330,"status":157,"phases":438,"primaryCompletion":332,"completion":332,"start":333,"enrollment":334,"conditions":439,"interventions":440},[48],[28],[318,337,338],{"trials":442,"activeCount":57},[],{"trials":444,"activeCount":57},[],{"intervention":338,"totalTrials":53,"cells":446},{"EARLY_PHASE1":447,"PHASE1":449,"PHASE2":451,"PHASE3":453,"PHASE4":459,"NA":461},{"trials":448,"activeCount":57},[],{"trials":450,"activeCount":57},[],{"trials":452,"activeCount":57},[],{"trials":454,"activeCount":57},[455],{"nctId":329,"briefTitle":330,"status":157,"phases":456,"primaryCompletion":332,"completion":332,"start":333,"enrollment":334,"conditions":457,"interventions":458},[48],[28],[318,337,338],{"trials":460,"activeCount":57},[],{"trials":462,"activeCount":57},[],{"intervention":350,"totalTrials":53,"cells":464},{"EARLY_PHASE1":465,"PHASE1":467,"PHASE2":469,"PHASE3":471,"PHASE4":477,"NA":479},{"trials":466,"activeCount":57},[],{"trials":468,"activeCount":57},[],{"trials":470,"activeCount":57},[],{"trials":472,"activeCount":57},[473],{"nctId":340,"briefTitle":341,"status":342,"phases":474,"primaryCompletion":344,"completion":345,"start":346,"enrollment":347,"conditions":475,"interventions":476},[48],[28],[350,318,351],{"trials":478,"activeCount":57},[],{"trials":480,"activeCount":57},[],{"intervention":351,"totalTrials":53,"cells":482},{"EARLY_PHASE1":483,"PHASE1":485,"PHASE2":487,"PHASE3":489,"PHASE4":495,"NA":497},{"trials":484,"activeCount":57},[],{"trials":486,"activeCount":57},[],{"trials":488,"activeCount":57},[],{"trials":490,"activeCount":57},[491],{"nctId":340,"briefTitle":341,"status":342,"phases":492,"primaryCompletion":344,"completion":345,"start":346,"enrollment":347,"conditions":493,"interventions":494},[48],[28],[350,318,351],{"trials":496,"activeCount":57},[],{"trials":498,"activeCount":57},[],{"intervention":500,"totalTrials":53,"cells":501},"Curosurf 80Mg\u002FMl Intratracheal Suspension",{"EARLY_PHASE1":502,"PHASE1":504,"PHASE2":506,"PHASE3":508,"PHASE4":519,"NA":521},{"trials":503,"activeCount":57},[],{"trials":505,"activeCount":57},[],{"trials":507,"activeCount":57},[],{"trials":509,"activeCount":57},[510],{"nctId":511,"briefTitle":512,"status":342,"phases":513,"primaryCompletion":514,"completion":514,"start":515,"enrollment":9,"conditions":516,"interventions":518},"NCT03959384","Efficacy and Safety of Curosurf® in Patients Invasively Ventilated for Severe Bronchiolitis Under 12 Months of Age",[48],"2021-04-09","2019-01-09",[517],"Bronchiolitis, Viral",[500],{"trials":520,"activeCount":57},[],{"trials":522,"activeCount":57},[],{"intervention":524,"totalTrials":53,"cells":525},"Acetylsalicylic acid",{"EARLY_PHASE1":526,"PHASE1":528,"PHASE2":530,"PHASE3":532,"PHASE4":545,"NA":547},{"trials":527,"activeCount":57},[],{"trials":529,"activeCount":57},[],{"trials":531,"activeCount":57},[],{"trials":533,"activeCount":57},[534],{"nctId":535,"briefTitle":536,"status":114,"phases":537,"primaryCompletion":538,"completion":539,"start":540,"enrollment":541,"conditions":542,"interventions":544},"NCT04808895","Acetylsalicylic Acid in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients With COVID-19",[48],"2021-07-01","2021-08-31","2021-04-01",204,[28,543],"Thrombosis Pulmonary",[524],{"trials":546,"activeCount":57},[],{"trials":548,"activeCount":57},[],{"intervention":550,"totalTrials":53,"cells":551},"Standard medical therapy",{"EARLY_PHASE1":552,"PHASE1":554,"PHASE2":556,"PHASE3":558,"PHASE4":571,"NA":573},{"trials":553,"activeCount":57},[],{"trials":555,"activeCount":57},[],{"trials":557,"activeCount":57},[],{"trials":559,"activeCount":57},[560],{"nctId":561,"briefTitle":562,"status":114,"phases":563,"primaryCompletion":564,"completion":565,"start":566,"enrollment":567,"conditions":568,"interventions":570},"NCT03827577","OMEGA, Local Ablative Therapy in Oligometastatic NSCLC",[48],"2022-03","2022-09","2019-10-01",195,[569],"Carcinoma, Non-Small-Cell Lung",[550],{"trials":572,"activeCount":57},[],{"trials":574,"activeCount":57},[],{"intervention":576,"totalTrials":53,"cells":577},"Vistabex",{"EARLY_PHASE1":578,"PHASE1":580,"PHASE2":582,"PHASE3":594,"PHASE4":596,"NA":598},{"trials":579,"activeCount":57},[],{"trials":581,"activeCount":57},[],{"trials":583,"activeCount":57},[584],{"nctId":585,"briefTitle":586,"status":114,"phases":587,"primaryCompletion":588,"completion":588,"start":589,"enrollment":590,"conditions":591,"interventions":593},"NCT05012566","Onabotulinumtoxin A and Hyaluronic Acid Fillers in the Treatment of Facial Paralysis",[47],"2023-07-14","2021-07-14",70,[592],"Hemifacial Paralysis",[576],{"trials":595,"activeCount":57},[],{"trials":597,"activeCount":57},[],{"trials":599,"activeCount":57},[],{"intervention":601,"totalTrials":53,"cells":602},"Libramed",{"EARLY_PHASE1":603,"PHASE1":605,"PHASE2":607,"PHASE3":619,"PHASE4":621,"NA":623},{"trials":604,"activeCount":57},[],{"trials":606,"activeCount":57},[],{"trials":608,"activeCount":57},[609],{"nctId":610,"briefTitle":611,"status":114,"phases":612,"primaryCompletion":613,"completion":614,"start":615,"enrollment":616,"conditions":617,"interventions":618},"NCT02148614","Effects of Intake of a Polysaccharides Mix on Metabolism, Hormones and Satiety in Obese Children.",[46,47],"2021-09","2021-12","2014-01",120,[23],[601],{"trials":620,"activeCount":57},[],{"trials":622,"activeCount":57},[],{"trials":624,"activeCount":57},[],{"intervention":626,"totalTrials":53,"cells":627},"COVID-19 treatment",{"EARLY_PHASE1":628,"PHASE1":630,"PHASE2":632,"PHASE3":634,"PHASE4":636,"NA":638},{"trials":629,"activeCount":57},[],{"trials":631,"activeCount":57},[],{"trials":633,"activeCount":57},[],{"trials":635,"activeCount":57},[],{"trials":637,"activeCount":57},[],{"trials":639,"activeCount":57},[640],{"nctId":641,"briefTitle":642,"status":114,"phases":643,"primaryCompletion":644,"completion":645,"start":646,"enrollment":647,"conditions":648,"interventions":651},"NCT04438629","Evaluation of Immune Response in COVID-19 Patients",[],"2020-06-10","2020-11-26","2020-03-26",80,[649,650],"Allergy and Immunology","Infection Viral",[626]]